EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial

John P Leonard iD, Marek Trněný iD, Huilai Zhang, Grzegorz S Nowakowski iD, Koji Izutsu iD, Nathan Fowler, Catherine Thieblemont iD, Pier Luigi Zinzani iD, Argyrios Gkasiamis, Jung Ryun Ahn, John G Gribben iD, AUGMENT Trial Investigators

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-25-01770 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von John P Leonard und 11 weiteren Autor:innen. Beteiligte Einrichtung: Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, New York, NY. Hauptthemen laut MEDLINE: Rituximab, Lenalidomide, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Follicular. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phase III AUGMENT trial (ClinicalTrials.gov identifier: NCT01938001 ) demonstrated improved efficacy for lenalidomide plus rituximab (R 2 ) versus rituximab with placebo (R-placebo) in patients with relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Here, we present the long-term follow-up results and prespecified subgroup analyses of patients with follicular lymphoma (FL), including those 70 years and older. Patients with R/R grade 1 to 3a iNHL were randomly assigned 1:1 to receive R 2 or R-placebo. In this long-term follow-up report, progression-free survival (PFS) was assessed per the investigator. Secondary end points included overall survival (OS) and safety. Of the 358 randomly assigned patients (intent-to-treat [ITT] population), 295 had FL (≥70 years, n = 66). At long-term follow-up (median, 65.9 months), in the ITT iNHL population, PFS (hazard ratio [HR], 0.50 [95% CI, 0.38 to 0.66]) and OS (HR, 0.59 [95% CI, 0.37 to 0.95]) were improved with R 2 versus R-placebo. Safety findings were consistent with the primary analysis. Improved long-term efficacy with R 2 versus R-placebo and manageable safety with R 2 were observed in patients with FL, including those 70 years and older. With a follow-up of >5 years, data from the AUGMENT trial continue to support the use of R 2 as a standard of care for patients with R/R iNHL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabLenalidomideAntineoplastic Combined Chemotherapy ProtocolsLymphoma, FollicularLymphoma, Non-HodgkinHumansAgedFemaleFollow-Up StudiesMaleMiddle AgedNeoplasm Recurrence, LocalProgression-Free SurvivalAged, 80 and overAdult

Substanzen

RituximabLenalidomide

Autor:innen und Institutionen

  • Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, New York, NY.
  • Charles University, General Hospital, Prague, Czech Republic.
  • Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.
  • Mayo Clinic, Rochester, MN.
  • National Cancer Center Hospital, Tokyo, Japan.
  • MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: John P Leonard, Marek Trněný, Grzegorz S Nowakowski, Koji Izutsu, Catherine Thieblemont, Pier Luigi Zinzani, John G Gribben

Zitieren

APA

Leonard, J. P., Trněný, M., Zhang, H., Nowakowski, G. S., Izutsu, K., Fowler, N., Thieblemont, C., Zinzani, P. L., Gkasiamis, A., Ahn, J. R., Gribben, J. G., & AUGMENT Trial Investigators (2026). Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01770

Vancouver

Leonard JP, Trněný M, Zhang H, Nowakowski GS, Izutsu K, Fowler N, et al. Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-01770

BibTeX
@article{Leonard2026,
  author = {Leonard, John P and Trněný, Marek and Zhang, Huilai and Nowakowski, Grzegorz S and Izutsu, Koji and Fowler, Nathan and Thieblemont, Catherine and Zinzani, Pier Luigi and Gkasiamis, Argyrios and Ahn, Jung Ryun and Gribben, John G and AUGMENT Trial Investigators, AUGMENT Trial Investigators},
  title = {Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-01770}
}
Kostenlos starten →